Patents Assigned to Sankyo Company Limited
  • ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
    Publication number: 20220364086
    Abstract: The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5? and/or 3? end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).
    Type: Application
    Filed: July 10, 2020
    Publication date: November 17, 2022
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, Tokai University Educational System
    Inventors: Makoto KOIZUMI, Akifumi NAKAMURA, Takahiro KATAGIRI, Hiroaki MITSUHASHI
  • Granules containing diamine derivative
    Patent number: 11497741
    Abstract: Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: November 15, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Wolfgang Schmid, Maren Kuhli, Christoph Schuh
  • METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES
    Publication number: 20220339260
    Abstract: As an approach of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells, provided is a method comprising the step of three-dimensionally culturing cells in a medium containing a dihydroindolizinone derivative.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 27, 2022
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shoen Kume, Nobuaki Shiraki, Tatsuya Yano, Toshihiro Kiho
  • Griseofulvin compound
    Patent number: 11472784
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 18, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Anti-CD147 antibody
    Patent number: 11459387
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 4, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke Fukuchi, Kayoko Nanai, Masato Amano, Kozo Yoneda, Yusuke Totoki, Shoji Yamamoto
  • KLK5 INHIBITORY PEPTIDE
    Publication number: 20220306725
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 29, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • Anti-CDH6 antibody and method of producing an anti-CDH6 antibody-drug conjugate
    Patent number: 11446386
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 20, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko Saito, Tsuyoshi Hirata, Kensuke Nakamura
  • Anti-ALK2 antibody
    Patent number: 11447554
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: September 20, 2022
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • Aminoalkyl compound
    Patent number: 11440896
    Abstract: The present invention directs to provide a novel compound for treating and/or preventing pain, having excellent skin permeation and reduced skin irritation.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: September 13, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Keisuke Suzuki
  • THERAPEUTIC AGENT FOR CANCER HAVING RESISTANCE TO ANTI-CCR4 ANTIBODY
    Publication number: 20220280492
    Abstract: An object of the present invention is to provide a therapeutic agent having an excellent effect on ATL patients with a history of treatment with an anti-CCR4 antibody, in other words, ATL patients who developed resistance to an anti-CCR4 antibody. An EZH1/2 dual inhibitor, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof was found to have an excellent effect on anti-CCR4 antibody-resistant cancer (particularly mogamulizumab-resistant cancer).
    Type: Application
    Filed: August 7, 2020
    Publication date: September 8, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Sumiaki FUJITANI
  • Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
    Patent number: 11434289
    Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 6, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji Iida, Takehiro Hirai, Tomoko Terauchi, Kensuke Nakamura
  • ANTIBODY RECOGNIZING EXTRACELLULAR REGION OF ALK2/ACVR1
    Publication number: 20220267453
    Abstract: This application provides: an antibody or an antigen-binding fragment thereof which can be used not only as a therapeutic drug but as a tool of immunological and immunohistological analysis such as immunostaining or Western blot, specifically recognizes an extracellular region polypeptide of human, mouse and rat ALK2, and inhibits BMP signal transduction, and an antibody or an antigen-binding fragment thereof which has a property of specifically binding to an extracellular region of ALK2 to form an ALK2 homodimer and a property of inhibiting the formation of an ALK2-type II receptor heterodimer, and inhibits the activation of ALK2 kinase, or inhibits BMP signal transduction; and a method for inhibiting the activation of ALK2 kinase or a method for inhibiting BMP signal transduction using the antibody or the antigen-binding fragment thereof.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 25, 2022
    Applicants: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu KATAGIRI, Sho TSUKAMOTO, Mai KURATANI
  • Griseofulvin compound and pharmaceutical use thereof
    Patent number: 11407746
    Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R1: a C1-C6 alkyl group or the like, R2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R3, R3?: a C1-C6 alkyl group or the like.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: August 9, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Makoto Hirasawa
  • NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
    Publication number: 20220226497
    Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).
    Type: Application
    Filed: March 30, 2022
    Publication date: July 21, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshio NISHI, Kohei SAKANISHI, Shigeru NOGUCHI, Tadahiro TAKEDA
  • Method for selecting individuals to be administered immune checkpoint inhibitor
    Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • PYRROLOPYRAZOLE DERIVATIVE
    Publication number: 20220185815
    Abstract: The present invention provides a low molecular compound that inhibits phosphatidylserine synthase 1 or a pharmaceutically acceptable salt thereof, a pharmaceutical containing thereof, and a therapeutic agent for cancer having a suppressed function of phosphatidylserine synthase 2. The compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein R1, ring Q1, ring Q2, and W are as defined in the specification.
    Type: Application
    Filed: March 5, 2020
    Publication date: June 16, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hidenori NAMIKI, Masanori SAITOU, Satoshi MATSUI, Yoshihiro SHIBATA, Yoshito KAWAMOTO, Rie ICHIKAWA, Yohei YOSHIHAMA, Akiko OTSUKA
  • ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
    Publication number: 20220177601
    Abstract: A novel anti-HER2 antibody-pyrrolobenzodiazepine (PBD) derivative conjugate, a medicine having therapeutic effect against tumor with the antibody-drug conjugate, and a method for treating a tumor by using the antibody-drug conjugate or medicine.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Naoya HARADA, Kozo YONEDA, Ichiro HAYAKAWA
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220172420
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: February 10, 2022
    Publication date: June 2, 2022
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE
    Publication number: 20220168440
    Abstract: A novel antibody-pyrrolobenzodiazepine (PBD) derivative conjugate, a medicine having therapeutic effect against tumor with the antibody-drug conjugate, and a method for treating a tumor by using the antibody-drug conjugate or medicine.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 2, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA
  • COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR
    Publication number: 20220168438
    Abstract: A pharmaceutical composition for treatment of cancer or a method for treating cancer, wherein an antibody-pyrrolobenzodiazepine derivative conjugate and a PARP inhibitor are administered in combination.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 2, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Naoya HARADA, Michiko KITAMURA